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ABSTRACT
Objectives: Communication of relevant prognostic
information is critical in helping patients understand
the implications of their cancer diagnosis. We describe
measures of prognosis to help communicate relevant
prognostic information to improve patients’
understanding of the implications of their cancer
diagnosis.
Setting: Australia-wide population-based cancer
registry cohort.
Participants: 870 878 patients aged 15–89 years
diagnosed with invasive cancer between 1990 and
2007, with mortality follow-up information to
December 2010.
Primary and secondary outcome measures:
Flexible parametric models were used to estimate loss
of life expectancy (LOLE), remaining life expectancy
(RLE) and 10-year cumulative probability of cancer-
specific death (1-relative survival).
Results: On average, Australians diagnosed with
cancer at age 40 years faced losing an average of
11.2 years of life (95% CI 11.1 to 11.4) due to their
cancer, while those diagnosed at 80 years faced losing
less, an average of 3.9 years (3.9 to 4.0) because of
higher competing mortality risks. In contrast, younger
people had lower estimated cumulative probabilities of
cancer-specific death within 10 years (40 years: 21.5%,
21.4% to 22.1%) compared with older people
(80 years: 55.4%, 55.0% to 55.9%). The patterns for
individual cancers varied widely, both by cancer type
and by age within cancer type.
Conclusions: The LOLE and RLE measures provide
complementary messages to standard relative
survival estimates (expressed here in terms of
cumulative probability of cancer-specific death).
Importantly, relative survival per se underplays the
greater absolute impact that a cancer diagnosis has
at a younger age on LOLE. When presented in
isolation for all cancers, it may provide a misleading
impression of future mortality burden of cancer
overall, and furthermore, it will obscure patterns of
mortality by type and by age data within type.
Alternative measures of LOLE, therefore, provide
important communication about mortality risk to
patients with cancer worldwide and should be
incorporated into standard reporting and
dissemination strategies.
INTRODUCTION
As the number of people diagnosed with
cancer increases and their average survival
lengthens,1 improving the quality and rele-
vance of survival information at the time of
diagnosis and during follow-up is critical.
While the majority of patients with cancer
want information on their survival prospects
and life expectancy,2 3 conveying this infor-
mation can be challenging. For example,
most patients have difﬁculty in understand-
ing probabilities.4 Access to a wider range of
measures regarding prognosis may assist in
tailoring the communication of mortality risk
to individual patients.
Various methods of expressing net survival
outcomes have been used, including relative5
and cause-speciﬁc survival.6 7 Recently, condi-
tional survival has been reported,8–10 which
is the expected survival after a patient has
already lived for a certain time. While each
of these measures of survival is important,
there are limitations in the application of
probabilities or percentages. For example, a
10-year survival estimate of 75% may mean
little to someone without an understanding
of their expected lifespan. In addition, all
measures of net survival reﬂect the fairly
uninformative probability (to the patient) of
surviving assuming the cancer under consid-
eration is the only cause of death.
Strengths and limitations of this study
▪ Large population-based national cohort of patients
with cancer with up to 21 years follow-up.
▪ Use of flexible parametric models to more easily
capture the shape of the underlying hazards func-
tion and extrapolate future survival estimates.
▪ No additional information about clinical
characteristics and management strategies.
▪ The use of population mortality rates may be
less valid for some patients with cancer due to
shared risk factors for other causes of deaths.
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Another indicator of prognosis is the impact that a
cancer diagnosis has on life expectancy,11 expressed
either as the difference between the life expectancy
among the general population and that of people diag-
nosed with cancer (loss of life expectancy or LOLE) or
the remaining life expectancy (RLE) among patients
with cancer. These approaches address the question “On
average, how much does my life expectancy change now
that I have been diagnosed with cancer?” While this
measure has intuitive appeal, its widespread use has
been limited by the lack of suitable methodology and
software to extrapolate the observed survival curve
beyond the available follow-up period.11 With the recent
development of new statistical methods,11 these esti-
mates of LOLE and RLE have potential for wider dis-
semination and clinical application.
In this article, we present population-based estimates
of LOLE and RLE due to cancer for patients diagnosed
in Australia, alongside a measure representing the stand-
ard relative survival estimates.
METHODS
Cancer cohort
Approval for the use of the data was provided by all of
the individual state and territory cancer registries
through the Australian Institute of Health and Welfare
(AIHW), with the exception of the Australian Capital
Territory (ACT). Residents of the ACT account for about
1.2% of all cancers diagnosed in Australia.1 No external
funding was obtained for this study.
Notiﬁcation of all invasive cancers (excluding keratino-
cyte skin cancers) to Australian state and territory
cancer registries is required by law. De-identiﬁed case
records for the whole of Australia (excluding ACT) were
obtained from the AIHW, to which the population state
and territory cancer registries supply data on an annual
basis.12 All patients with cancer diagnosed from 1990 to
2007 were included in the cancer cohort, with follow-up
of mortality status to 31 December 2010. Variables pro-
vided in the data extract were unique identiﬁer, month
and year of diagnosis, month and year of death
(if applicable), days between diagnosis and either death
or date of last follow-up (whichever came ﬁrst), sex, age
at diagnosis, type of cancer, and basis of diagnosis. We
restricted our cancer cohort to patients aged 15–89 years
at diagnosis due to different cancer classiﬁcations being
used for children13 and for consistency with our recent
conditional survival analysis.8 Mortality status was
obtained through the routine annual linkage of cancer
records with the National Death Index in Australia. The
incidence data up to 2007 were the most recent to have
been matched to the National Death Index; therefore,
patients diagnosed after 2007 would be likely to have
more incomplete mortality information.
In addition to all invasive cancers combined
(International Classiﬁcation of Diseases (ICD)-O-3 codes
C00-C80), we restricted the cancer-speciﬁc analyses to
stomach cancer (C16), colorectal cancer (C18-C20,
C218), lung cancer (C33-C34), melanoma of the skin
(C44, M872-M879), breast cancer among females (C50)
and prostate cancer (C61). These major types of cancer
also serve to illustrate a range of survival outcomes.
Cases diagnosed on the basis of death certiﬁcate only or
when the recorded date of diagnosis was after the date
of death were excluded from the cohort.
Statistical methods
At-risk period
Since the mortality follow-up period extended beyond
the diagnostic study period, we applied the hybrid
period survival method described by Brenner and
Rachet.14 Under this approach, members of the cancer
cohort were considered to be ‘at risk’ of dying during
the 5-year period between 1 January 2006 and 31
December 2010. However, as the follow-up period
extends beyond the period from which incident cases
are accrued, there are fewer years of cases available for
the period 2008–2010 during the ﬁrst 3 years of
follow-up. The ‘at-risk’ window is, therefore, altered to
ensure that each follow-up interval consists of 5 years of
cases. For the ﬁrst year of follow-up, we extended the
‘at-risk’ window to 2003–2007, for the second year to
2004–2008, for the third year to 2005–2009 and then to
2006–2010 for subsequent years of follow-up. For those
who died before 31 December 2010, observed survival
time was measured from the date of diagnosis to the
date of death, with survival being censored at 31
December 2010 for those patients still alive at that date.
Relative survival
We used relative survival to approximate disease-speciﬁc
survival because it does not require any information on
the cause of death.5 Relative survival is calculated by div-
iding the observed probability of all-cause survival
among individuals diagnosed with a speciﬁc cancer by
the expected probability of survival within the
age-sex-year-matched general population of Australia.
Expected survival was obtained from the Ederer II
method15 using Australian population life tables. To
allow a more direct comparison with RLE and LOLE, we
have reported the cumulative probability of death, which
is equal to one minus the relative survival.
LOLE and RLE
The theoretical concepts of LOLE and RLE are illu-
strated in ﬁgure 1. The RLE for a hypothetical cohort of
patients with cancer is represented by the area under
the observed survival curve (lower red solid line), with
survival time on the x-axis. The area under the expected
survival curve (upper green dashed line) represents the
life expectancy of the age-sex-year-matched general
population. The difference between these two measures,
that is, the blue shaded area between the two curves,
represents the LOLE from the time of diagnosis
onwards.
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An important difference between relative survival and
either RLE or LOLE is that relative survival estimates
compare the observed and expected survival at only one
point on the survival curves (according to time after
diagnosis). In ﬁgure 1, 10-year relative survival is calcu-
lated by dividing the value at point B by the value at
point A. In contrast, RLE and LOLE consider the differ-
ences between all points on the two survival curves, thus
using a greater range of information, including the
length of the survival curve, in order to provide a more
complete picture of the changed mortality risks experi-
enced by those diagnosed with cancer.
Flexible parametric models
Owing to the limited time period covered by Australian
(and most international) population-based cancer regis-
tries, calculating the LOLE requires the extrapolation of
both the expected and observed survival curves beyond
the available follow-up period.11 To address this
concern, we used methods developed by Andersson
et al11 which used ﬂexible parametric models16 17 to
model the observed survival curves and then extrapo-
lated these to estimate the survival curves for additional
follow-up intervals.
Flexible parametric survival models use restricted
cubic splines for the baseline and can, therefore, more
readily capture the shape of the underlying hazard func-
tion compared with more traditional methods, such as
the Cox proportional hazards model.11 We imposed 7
degrees of freedom (or 6 internal ‘knots’) for the base-
line function and 4 degrees of freedom (3 internal
‘knots’) for the time-varying effects,11 and used
restricted cubic splines with 4 degrees of freedom and a
time-varying component to model the effect of age.
Extrapolation of the observed curves using these
models requires making assumptions for what happens
beyond the last observed follow-up interval. A previous
study11 has demonstrated that assuming a linear trend in
the log cumulative excess hazard ﬁtted the observed
survival well; therefore, for simplicity we followed the
same approach with our models.
Estimates for relative survival, cumulative probability of
death, RLE and LOLE were predicted from the ﬂexible
parametric models for single years of age and then
reported for each cancer type at 40, 50, 60, 70 and
80 years of age. Median follow-up time was calculated
using the reverse Kaplan-Meier method.18 The propor-
tion of life expectancy lost due to the cancer diagnosis
was calculated by dividing the LOLE by the population
life expectancy.
All statistical analyses were performed using Stata/SE
V.12.1 for Windows (StataCorp, Texas, USA). Flexible
parametric survival models were ﬁtted using the stpm2
package.17 18
RESULTS
A total of 1 474 744 Australians were diagnosed with
cancer between 1990 and 2007. Of these 359 (0.02%)
were excluded due to missing or negative follow-up
times and 14 709 (1%) were excluded due to the diag-
nosis being based on death certiﬁcate only. Of the
remaining patients, 870 878 (59%) were alive at some
point during the at-risk period and so formed the ﬁnal
cohort for this study. Key characteristics of these patients
with cancer are shown in table 1. Breast and prostate
cancer accounted for the largest proportion of cases
(16% each) followed by melanoma (14%) and colorec-
tal cancer (13%). The median age at diagnosis was
65–69 years for most speciﬁed types of cancer but was
about 10 years younger for melanoma and breast cancer.
Not considering the sex-speciﬁc breast and prostate
cancers, the majority of cases for each type of cancer
were diagnosed among males. The median time of
follow-up among the cohort ranged from 5.7 to 6.3 years
for the different cancer types. The proportion of
patients who died during the ‘at-risk’ period ranged
from 14% for melanomas to 77% for lung cancer.
Figure 1 Example illustration of
relationship between relative
survival (calculated as the ratio of
B:A at specific points along the
curve) and the loss of life
expectancy (calculated as the
area between the survival
curves).
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The effect that age had on the 10-year cumulative
probability of death varied by cancer type. For all
cancers combined, lung cancer, melanoma and, to a
lesser extent, stomach cancer, the curve increased with
age (table 2 and ﬁgure 2). In contrast, breast cancer and
prostate cancer showed a U-shaped curve in mortality,
while the curve for colorectal cancer was almost ﬂat
until it reached the older age groups.
Conversely, the effect that age had on LOLE was sub-
stantially more pronounced and consistent. Australians
diagnosed with cancer at younger ages had higher
LOLE estimates than those diagnosed at an older age
(table 2 and ﬁgure 3). LOLE depends on prognosis and,
more importantly, on population life expectancy, which
reduces with increasing age (table 2). To the extent that
both change with age, LOLE patterns will be impacted.
Using lung cancer as an example, a person diagnosed
when at 40 years of age (10 years probability of death:
78.2%) faced losing on average 33 years of life expect-
ancy (RLE=10 years), while a person aged 80 years at
diagnosis (10 years probability of death: 92.0%) faced
losing 7 years of life expectancy (RLE=1 year). When we
calculated the LOLE as a proportion of population life
expectancy, it increased steadily with age for all cancers
combined (table 2). However, when examined within
speciﬁc cancer types, proportional life expectancy was
much more stable for each cancer type, indicating that
the pattern seen with all cancer types resulted from the
change in the mix of cancers seen at different ages.
Differences between individual cancers by age reﬂected
variation in prognosis by type of cancer, with modest var-
iations by age within type (table 2).
DISCUSSION
The communication of relevant prognostic information
is critical in helping patients understand the implica-
tions of their cancer diagnosis. Most patients with cancer
wish to have accurate information regarding their prog-
nosis and life expectancy delivered in a way that is rele-
vant to them and easy to understand.2 3 By applying
emerging statistical models, we have demonstrated the
complementary messages provided by standard relative
survival statistics, and LOLE or RLE information.
Importantly, relative survival tends to underplay the
greater impact that a cancer diagnosis has at a younger
age and, when presented in isolation, may provide a mis-
leading impression of future mortality burden.
The measures of LOLE and RLE, which are expressed
in years, place greater importance on cancers diagnosed
in the early-middle years of life than relative survival.
This focus provides a better quantitative understanding
of the impact that a cancer has on the subsequent lives
of patients and the overall cancer burden. With some
exceptions (breast and prostate in this study), relative
survival estimates suggest that people diagnosed with
cancer do equally well between 40 and 70 years of age,
although people diagnosed at older ages tend to do
worse. However, by incorporating the implications on
life expectancy, the LOLE and RLE measures provide an
important different perspective, highlighting the greater
impact of a cancer diagnosis on the absolute LOLE
among younger people.
In spite of these new measures, relative survival retains
a high importance when disseminating information
about the burden of cancer. Relative survival (or cumula-
tive probability of death) compares the survival in differ-
ent ages in the hypothetical scenario that cancer was the
only possible cause of death (under some assumptions).
It is, therefore, the best way of making comparisons in
relation to age equity in quality of cancer care that are
free of differences due to other causes of mortality.
There are important differences in LOLE and the
contextually similar years of life lost (YLL) which is
often used to quantify premature mortality.19 First, YLL
requires accurate cause of death information, which is
avoided in LOLE since it is based on relative survival.
More importantly, YLL is based only on people dying
from the condition within a speciﬁc time period, irre-
spective of when they were diagnosed, thus ignoring the
experience of the entire cohort diagnosed with the con-
dition. In contrast, LOLE focuses on a deﬁned cancer
cohort and estimates the loss in expectation of life for
that cohort, or for recently diagnosed patients if a
(hybrid) period approach is used, irrespective of when
or if they die due to cancer.
Table 1 Characteristics of study cohort, Australia, diagnosed between 1990 and 2007 and ‘at risk’ between 2006 and 2010*
Cancer type
Eligible
incident cases
Median
age (years) Males (%)
Number of deaths (%)
(all causes combined)
Stomach cancer 11 591 69 65 6715 (58)
Colorectal cancer 115 804 67 54 38 140 (33)
Lung cancer 44 926 69 62 34 667 (77)
Melanoma 119 552 56 54 17 153 (14)
Breast cancer 143 313 57 0 22 406 (16)
Prostate cancer 141 645 68 100 35 248 (25)
All cancers combined† 870 878 63 53 261 720 (30)
*See methods for details of the at-risk period.
†Includes all cancers (excluding keratinocyte skin cancers), not just those cancers specified in this table.
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While relative survival and LOLE present different pic-
tures in terms of age-speciﬁc impacts, comparisons of
the mortality burden across cancer types show similar
case histories. Cancers with a low relative survival (and
high cumulative probability of death) have consistently
higher LOLE. For example, the age-speciﬁc LOLE for
melanoma (high survival, low cumulative probability of
death) was much lower than the corresponding
estimates for lung cancer and stomach cancer (low sur-
vival, high cumulative probability of death).
Both relative survival and LOLE are based on compar-
ing the observed mortality among the cancer cohort
with the population mortality and then attributing any
differences to the diagnosed cancer. This may not always
be the case, because people diagnosed with some
cancers typically have a higher prevalence of risk factors
Table 2 Cumulative probability of death (1-relative survival) and life expectancy by type of cancer and age at diagnosis, for
people diagnosed with cancer in Australia between 1990 and 2007 and at risk* between 2006 and 2010 (95% CIs in
brackets)
Age at
diagnosis
(years)
10-Year cumulative
probability of death
Life expectancy
Population life
expectancy
Cohort RLE
(years) LOLE (years)
Proportion of life
expectancy lost†
All cancers combined
40 21.7 (21.4 to 22.1) 43.2 32.0 (31.8 to 32.2) 11.2 (11.1 to 11.4) 0.26
50 28.3 (28.0 to 28.7) 33.6 23.1 (23.0 to 23.2) 10.5 (10.4 to 10.6) 0.31
60 33.2 (32.9 to 33.5) 23.9 15.9 (15.8 to 16.0) 8.0 (7.9 to 8.0) 0.33
70 43.1 (42.8 to 43.5) 15.2 9.3 (9.2 to 9.3) 6.0 (5.9 to 6.0) 0.39
80 55.4 (55.0 to 55.9) 8.5 4.6 (4.6 to 4.6) 3.9 (3.9 to 4.0) 0.46
Stomach
40 68.6 (65.0 to 72.2) 42.4 13.6 (12.1 to 15.2) 29.3 (27.7 to 30.8) 0.68
50 72.1 (69.7 to 74.5) 32.5 9.5 (8.7 to 10.3) 23.1 (22.3 to 23.9) 0.71
60 71.9 (70.1 to 73.7) 23.1 7.2 (6.8 to 7.7) 16.1 (15.7 to 16.5) 0.69
70 72.3 (70.2 to 74.3) 14.6 5.0 (4.8 to 5.3) 10.0 (9.8 to 10.3) 0.67
80 81.2 (79.0 to 83.3) 8.2 2.3 (2.2 to 2.5) 6.2 (6.0 to 6.3) 0.73
Colorectal
40 35.1 (33.7 to 36.6) 42.7 28.0 (27.3 to 28.6) 14.7 (14.0 to 15.3) 0.34
50 36.1 (35.1 to 37.1) 32.9 21.5 (21.2 to 21.9) 11.5 (11.1 to 11.8) 0.35
60 36.2 (35.5 to 37.0) 23.5 15.7 (15.5 to 15.9) 8.0 (7.8 to 8.2) 0.34
70 38.3 (37.5 to 39.2) 15.1 10.3 (10.1 to 10.4) 5.1 (5.0 to 5.2) 0.33
80 41.0 (39.7 to 42.2) 8.4 5.7 (5.6 to 5.8) 3.0 (2.9 to 3.1) 0.35
Lung
40 76.0 (73.8 to 78.1) 42.6 10.2 (9.2 to 11.1) 32.6 (31.6 to 33.5) 0.76
50 84.2 (83.2 to 85.1) 32.8 5.6 (5.3 to 5.9) 27.5 (27.2 to 27.8) 0.83
60 87.9 (87.3 to 88.4) 23.2 3.6 (3.5 to 3.8) 20.1 (20.0 to 20.3) 0.85
70 89.0 (88.4 to 89.6) 14.7 2.6 (2.6 to 2.7) 12.7 (12.6 to 12.8) 0.83
80 93.2 (92.6 to 93.8) 8.1 1.3 (1.3 to 1.4) 7.2 (7.1 to 7.2) 0.84
Melanoma
40 6.7 (6.1 to 7.3) 42.7 39.7 (39.4 to 40.1) 3.0 (2.7 to 3.4) 0.07
50 8.0 (7.5 to 8.6) 33.1 30.5 (30.2 to 30.7) 2.7 (2.5 to 2.9) 0.08
60 10.3 (9.6 to 11.0) 23.6 21.4 (21.2 to 21.5) 2.3 (2.2 to 2.5) 0.10
70 13.6 (12.6 to 14.8) 15.0 13.4(13.3 to 13.6) 1.8 (1.6 to 1.9) 0.12
80 17.4 (15.5 to 19.5) 8.2 7.4 (7.3 to 7.5) 1.0 (0.9 to 1.1) 0.12
Female breast
40 18.0 (17.3 to 18.8) 44.6 32.5 (31.9 to 33.1) 12.1 (11.5 to 12.7) 0.27
50 14.2 (13.7 to 14.7) 35.0 28.2 (27.9 to 28.5) 6.9 (6.6 to 7.1) 0.20
60 13.8 (13.2 to 14.3) 25.7 21.6 (21.5 to 21.8) 4.1 (3.9 to 4.2) 0.16
70 16.0 (15.2 to 17.0) 16.8 14.4 (14.3 to 14.6) 2.5 (2.3 to 2.6) 0.15
80 22.9 (21.3 to 24.7) 9.3 7.9 (7.8 to 8.0) 1.6 (1.5 to 1.7) 0.16
Prostate
40 12.3 (8.7 to 17.2) 40.8 33.7 (30.0 to 37.5) 7.0 (3.3 to 10.7) 0.17
50 7.9 (7.1 to 8.9) 31.4 27.8 (27.2 to 28.5) 3.6 (3.0 to 4.3) 0.12
60 7.3 (6.7 to 7.8) 22.4 20.2 (20.0 to 20.5) 2.2 (2.0 to 2.4) 0.10
70 12.4 (11.6 to 13.3) 13.9 12.5 (12.4 to 12.6) 1.6 (1.5 to 1.7) 0.12
80 31.1 (29.4 to 32.9) 7.5 6.3 (6.3 to 6.4) 1.5 (1.4 to 1.5) 0.19
*See methods for details of the at-risk period.
†Proportion of life expectancy lost=LOLE/population life expectancy.
LOLE, loss of life expectancy; RLE, remaining life expectancy.
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(such as smoking in patients with lung cancer) and
comorbidities. However, as this limitation applies to both
measures it would have minimal impact on any compari-
son between the two. The impact of factors, such as
comorbidities, could be assessed for the RLE and LOLE
if information on comorbidities was available for the
patients with cancer, and if population mortality rates
stratiﬁed on comorbidities were available.
We have purposefully used the hybrid period survival
method to focus on the survival predictions for recently
diagnosed patients, while also accessing the longer
follow-up of people diagnosed during the 1990s to
provide information about deaths in longer term sur-
vival cases; this assists in providing more certainty for the
extrapolation of the survival curves. This is different to
the cohort survival approach, in which the survival
experience of people diagnosed during the 1990s would
contribute to both short-term and long-term survival.
Since survival for most cancers has increased over time,1
the long-term survival of patients diagnosed recently
may be higher than those diagnosed in the early 1990s;
in other words, these LOLE estimates will overstate the
true values for recently diagnosed patients if this cohort
method is used.
However, these results still rely on extrapolated infor-
mation; therefore, caution is needed in case this does
not reﬂect the observed results 30 or 40 years postdiag-
nosis. It is also important to keep in mind that the CIs
presented for the LOLE and RLE only take uncertainty
in the model parameters into account and not uncer-
tainty in the extrapolation or model selection. In their
original development of this method, Andersson et al11
compared predicted survival outcomes for Swedish
patients diagnosed in the 1960s against actual survival
up to 2010 and found that the components of the ﬂex-
ible parametric method were robust, particularly when
Figure 2 Estimates of 10-year
cumulative probability of death
(1-relative survival) by age at
diagnosis and cancer type.
Figure 3 Estimated loss of life
expectancy (LOLE) by cancer
type and age at diagnosis.
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at least some of the cohort had more than 10 years of
follow-up, as is the case in our study. Finally, these esti-
mates are based on the averaging of population data
and will vary from patient to patient depending on their
speciﬁc circumstances. The same limitation applies with
routinely published relative survival estimates. Further
work is needed to examine the effect of clinical
characteristics on LOLE and RLE, particularly stage at
diagnosis, and how these measures change the longer
the patient survives their initial diagnosis (analogous to
conditional survival estimates). In addition, there is
potential to investigate the changing economic impact
of LOLE among younger people due to cancer for their
surviving dependents in light of the advancement of the
retirement age in Australia.
In conclusion, given the increasing numbers of people
being diagnosed with cancer and the improving survival
outcomes for most types of cancer, providing patients
with relevant risk information is paramount. LOLE and
RLE are an important addition to existing measures that
give a more complete picture of the impact of a cancer
diagnosis.
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